Compare Neurocrine Biosciences Inc (NBIX) vs Pinterest Inc (PINS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Pinterest Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Pinterest Inc trades at $21.4 (market cap $11.63B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Pinterest Inc is more actively traded (12,792,940 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Pinterest Inc for 85 Days on average.
| NBIX | PINS | |
|---|---|---|
Market Cap | $14.36B | $11.63B |
Volume | 1,237,180 | 12,792,940 |
Sector | Health | Media |
52-Week High | $185.50 | $35.24 |
52-Week Low | $123.10 | $15.42 |
Typical Hold Time | 23 Days | 85 Days |
Enterprise Value | $14.37B | $11.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Pinterest (PINS) trades at $20.525, up 1.06% with a bullish technical signal despite mixed oscillators. The company demonstrates strong revenue growth from $2.8B in 2022 to $4.2B in 2025, with consistent earnings beats in recent quarters. Analyst consensus is strongly positive with 54% buy ratings and a $27.93 price target, representing 36% upside potential from current levels.
PINS offers compelling growth potential driven by international monetization and visual search advertising innovations, though elevated valuation metrics (P/E 60.38) and insider selling activity warrant caution. The stock's primary catalysts include continued user growth and advertising revenue expansion, while risks center on competitive pressure and execution challenges in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
